Money’s senior healthcare writer Elizabeth O’Brien explains the difference between diagnostic and antibody tests and the advances that newer iterations need to make when it comes to speed and accuracy.

In this week’s episode, we speak with Erin Griffith of The New York Times about the impact of the pandemic on start-up activity and the VC community.

In this week’s episode we speak with public school teacher Rebecca Martinson on why she won’t risk the health and safety of her family by going back into live classroom teaching.

In this week's episode we’re joined by Jan Benzel, a 30-year veteran of the New York Times, who chronicled the miraculous survival of one of New York's early COVID patients, Larry Kelly, and how his journey mirrored that of the city in which he lives.

In this week's episode, Michael Brown, co-editor of The Deal, and veteran financial reporter Charlie Paikert discuss the pandemic’s impact on corporate mergers and acquisitions.

We talk with our guest this week, Julie Hyman of YahooFinance, about companies big and small having to manage their businesses and employees around the complexities of the coronavirus—and now finally—a larger focus on social justice issues.

Melinda Wenner Moyer writes a column for Slate and is a contributing editor at Scientific American magazine – she writes for the New York Times, Mother Jones, and a number of women’s magazines.

Misinformation about COVID-19 seems to spread faster than microbes. In this episode, Emmy-award winning journalist, author, professor and epidemiologist, Dr. Seema Yasmin, helps separate the fact from the fiction.

As the United States continues to see record-breaking new coronavirus cases, the country's reopening has become one of today's most critical topics. We discuss the issue with Forbes' reporter Alexandra Sternlicht and examine the unsettling resurgence, complications with testing, and the disproportionate impact of the virus on communities of color.

In this week's episode, journalist Christina Farr gives her shortlist of the companies to watch from CNBC's Disruptor 50, relays riveting first-hand accounts from heroes on the front lines of the pandemic, and weighs in on why the road to effective contract tracing in the United States is proving to be a not-so-simple path.